JP2013519699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519699A5 JP2013519699A5 JP2012553267A JP2012553267A JP2013519699A5 JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5 JP 2012553267 A JP2012553267 A JP 2012553267A JP 2012553267 A JP2012553267 A JP 2012553267A JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- domain
- fviii
- another embodiment
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 38
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 38
- 108010054218 Factor VIII Proteins 0.000 claims description 18
- 102000001690 Factor VIII Human genes 0.000 claims description 18
- 229960000301 factor viii Drugs 0.000 claims description 18
- 230000004927 fusion Effects 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 108010087819 Fc receptors Proteins 0.000 claims description 11
- 102000009109 Fc receptors Human genes 0.000 claims description 11
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 10
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 102000002110 C2 domains Human genes 0.000 claims description 3
- 108050009459 C2 domains Proteins 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 230000004989 O-glycosylation Effects 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10153715 | 2010-02-16 | ||
| EP10153715.7 | 2010-02-16 | ||
| US30617710P | 2010-02-19 | 2010-02-19 | |
| US61/306,177 | 2010-02-19 | ||
| PCT/EP2011/051959 WO2011101284A1 (en) | 2010-02-16 | 2011-02-10 | Factor viii fusion protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016021624A Division JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519699A JP2013519699A (ja) | 2013-05-30 |
| JP2013519699A5 true JP2013519699A5 (enExample) | 2015-07-02 |
Family
ID=42244627
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553267A Withdrawn JP2013519699A (ja) | 2010-02-16 | 2011-02-10 | 因子viii融合タンパク質 |
| JP2016021624A Expired - Fee Related JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
| JP2017144266A Withdrawn JP2017190342A (ja) | 2010-02-16 | 2017-07-26 | 因子viii融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016021624A Expired - Fee Related JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
| JP2017144266A Withdrawn JP2017190342A (ja) | 2010-02-16 | 2017-07-26 | 因子viii融合タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9493543B2 (enExample) |
| EP (2) | EP2536754A1 (enExample) |
| JP (3) | JP2013519699A (enExample) |
| CN (2) | CN102770450B (enExample) |
| WO (1) | WO2011101284A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| JP5914363B2 (ja) * | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
| EP2804623B1 (en) * | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| EP2822577B1 (en) * | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| WO2013160005A1 (en) | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| JP6618892B2 (ja) | 2013-04-23 | 2019-12-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 細菌バイオフィルムの遺伝的リプログラミング |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| EP3114138B1 (en) * | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6516829B2 (ja) | 2014-08-04 | 2019-05-22 | シーエスエル、リミテッド | 第viii因子製剤 |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| WO2016164422A2 (en) * | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Biosynthetic amyloid-based materials displaying functional protein sequences |
| WO2016198521A1 (en) * | 2015-06-10 | 2016-12-15 | Novo Nordisk A/S | Fviii fusion proteins |
| CN104926946B (zh) * | 2015-07-13 | 2021-09-17 | 中国科学院广州生物医药与健康研究院 | 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用 |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| EP3334452A4 (en) | 2015-08-12 | 2019-04-17 | Cell Machines, Inc. | METHOD AND COMPOSITIONS IN CONJUNCTION WITH COMBUSTION COMPLEXES WITH LONG HALF TIME |
| GB201520021D0 (en) * | 2015-11-13 | 2015-12-30 | Asterion Ltd | Fusion polypeptide |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US11098133B2 (en) | 2016-05-19 | 2021-08-24 | President And Fellows Of Harvard College | Methods of making gels and films using curli nanofibers |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| CN108623695B (zh) * | 2017-03-24 | 2022-03-15 | 中国科学院过程工程研究所 | 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用 |
| AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| GB201706781D0 (en) | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| WO2019219048A1 (zh) * | 2018-05-18 | 2019-11-21 | 北京辅仁瑞辉生物医药研究院有限公司 | 具有延长半衰期的融合多肽缀合物 |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| WO2019219049A1 (zh) * | 2018-05-18 | 2019-11-21 | 北京辅仁瑞辉生物医药研究院有限公司 | 改进的fviii融合蛋白及其应用 |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技(上海)有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| EP4017521A1 (en) * | 2019-09-02 | 2022-06-29 | Biotest AG | Factor viii protein with increased half-life |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4058049A1 (en) | 2019-11-11 | 2022-09-21 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| CN114901671B (zh) * | 2020-01-20 | 2024-02-20 | 上海药明生物技术有限公司 | 用于亲和层析的新的清洗缓冲溶液 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| IL301332A (en) * | 2020-09-23 | 2023-05-01 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of autoantibody-mediated conditions |
| EP4534563A1 (en) * | 2022-05-25 | 2025-04-09 | Jiangsu Gensciences Inc. | Fviii fusion protein conjugate having extended half-life and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3879395T2 (de) | 1987-05-29 | 1993-06-24 | Central Glass Co Ltd | Fusionsprotein, enthaltend lymphotoxin. |
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
| US6939677B1 (en) | 1990-11-01 | 2005-09-06 | Cancer Research Fund Of Contra Costa | Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6524572B1 (en) | 2000-06-26 | 2003-02-25 | Rainbow Therapeutic Company | Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| CA2512974A1 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Soluble fc.gamma.r fusion proteins and methods of use thereof |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| US20070106066A1 (en) | 2003-10-28 | 2007-05-10 | Alexander Cherkasky | Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions |
| US20070275873A1 (en) | 2004-04-29 | 2007-11-29 | Heidner Hans W | Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting |
| WO2006102652A2 (en) | 2005-03-24 | 2006-09-28 | Neose Technologies, Inc. | Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| WO2007065691A2 (en) | 2005-12-07 | 2007-06-14 | Technische Universität München | Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins |
| US20090053790A1 (en) | 2006-01-31 | 2009-02-26 | Ishihara Sangyo Kaisha, Ltd. | Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell |
| ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| WO2008068280A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| CA2673459C (en) * | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| CA2676098A1 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble fcgammaria and related methods |
| US8043621B2 (en) | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| AU2008314697B2 (en) | 2007-10-22 | 2013-08-29 | Merck Serono S.A. | Single IFN-beta fused to a mutated lgG Fc fragment |
| DK2257311T3 (da) * | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Konjugerede Faktor VIII-Molekyler |
| DK2865760T3 (en) * | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
-
2011
- 2011-02-10 US US13/574,686 patent/US9493543B2/en not_active Expired - Fee Related
- 2011-02-10 CN CN201180009864.4A patent/CN102770450B/zh not_active Expired - Fee Related
- 2011-02-10 CN CN201510524808.4A patent/CN105153313A/zh not_active Withdrawn
- 2011-02-10 WO PCT/EP2011/051959 patent/WO2011101284A1/en not_active Ceased
- 2011-02-10 EP EP11703448A patent/EP2536754A1/en not_active Withdrawn
- 2011-02-10 JP JP2012553267A patent/JP2013519699A/ja not_active Withdrawn
- 2011-02-10 EP EP15159991.7A patent/EP2977055A1/en not_active Withdrawn
-
2016
- 2016-02-08 JP JP2016021624A patent/JP6185097B2/ja not_active Expired - Fee Related
- 2016-10-04 US US15/285,138 patent/US20170015729A1/en not_active Abandoned
-
2017
- 2017-07-26 JP JP2017144266A patent/JP2017190342A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6559642B2 (ja) | Fviiiの特定部位の変更 | |
| JP6527918B2 (ja) | 第viii因子組成物、ならびに組成物の作製方法および用途 | |
| JP2018104459A (ja) | 血友病の治療に適する化合物 | |
| JP2017503509A5 (enExample) | ||
| JP6605593B2 (ja) | 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤 | |
| JP2015527882A5 (enExample) | ||
| JP2016522219A (ja) | 血友病の治療に適する化合物 | |
| JP2015519313A (ja) | 血友病の治療に適する医薬組成物 | |
| JP2023134586A (ja) | Siglec依存的免疫応答をモジュレートするポリペプチド | |
| JP2005535588A (ja) | 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト | |
| WO2020063562A1 (zh) | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 | |
| JP2024526356A5 (enExample) | ||
| WO2017050820A1 (en) | Fviii fusion proteins | |
| JP2026513540A (ja) | 薬物動態が改善されたfviii-vwf融合タンパク質 |